Author

E. Haura

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Marusyk· 2 shared B. Desai· 2 shared G. Zhang· 2 shared J. Scott· 2 shared V. Marusyk· 2 shared A. C. Tan· 1 shared A. Dhawan· 1 shared A. Durmaz· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Marusyk

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Peristromal niches protect lung cancers from targeted therapies through a combined effect of multiple molecular mediators

B. Desai, T. Miti, S. Prabhakaran, D. Miroshnychenko, M. Henry, V. Marusyk, C. Gatenbee, M. Bui, J. Scott, P. M. Altrock, E. Haura, A. R. A. Anderson, D. Basanta, A. Marusyk

This study shows that stromal niches protect lung cancers from ALK inhibitors through multiple mechanisms, and targeting these mechanisms together is more effective than targeting them individually.

bioRxiv · Apr 24, 2024 · PreprintCancer Biology

Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML

C. Letson, M. E. Balasis, H. Newman, M. Binder, A. Vedder, F. Kinose, M. Ball, T. Kruer, A. Quintana, T. L. Lasho, C. M. Finke, L. L. Almada, J. M. Grants, G. Zhang, M. E. Fernandez-Zapico, , E. Padron

This study identifies PIM inhibitors as synergistic with BET inhibitors in myeloid leukemia, showing miR-33a downregulation drives PIM1 upregulation and GM-CSF hypersensitivity as a biomarker for combination therapy.

bioRxiv · Nov 1, 2022Cancer Biology

Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer

K. Ross, G. Zhang, C. Akcora, Y. Lin, B. Fang, J. Koomen, E. Haura, M. Grimes

The paper uses machine learning to analyze PTM data from lung cancer cell lines, identifying functional modules and networks that reveal crosstalk between signaling pathways and metabolic processes in response to TKIs.

bioRxiv · Oct 28, 2022Cancer Biology

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures

R. Vander Velde, N. Yoon, V. Marusyk, A. Durmaz, A. Dhawan, D. Myroshnychenko, D. Peral, B. Desai, O. Balynska, J. Poleszhuk, K. Liu, M. Abazeed, A. C. Tan, O. Mian, E. Haura, , A. Marusyk

The paper investigates resistance to ALK inhibitors in NSCLC, finding that resistance develops through gradual, multifactorial genetic and epigenetic changes rather than single mutations or reprogramming.

bioRxiv · Nov 19, 2019Cancer Biology